DMD Simcyp - the leader in IVIVE

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 2, 2008; DOI: 10.1124/dmd.107.020016

This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kanebratt, K. P.
Right arrow Articles by Andersson, T. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanebratt, K. P.
Right arrow Articles by Andersson, T. B.


Received for publication December 6, 2007.
Revised February 29, 2008.
Accepted for publication April 1, 2008.

Evaluation of HepaRG Cells as an In Vitro Model for Human Drug Metabolism Studies

Kajsa P. Kanebratt 1 Tommy B. Andersson 2*

1 AstraZeneca R&D Molndal 2 Astra Zeneca Research and Development MoIndal

* Address correspondence to: E-mail: tommy.b.andersson{at}astrazeneca.com

Abstract

HepaRG cells, a newly developed human hepatoma cell line, differentiate into hepatocyte like morphology by treatment with dimethyl sulfoxide (DMSO). The expression of cytochrome P450 (P450) enzymes, transporter proteins and transcription factors were stable in differentiated HepaRG cells over a period of six weeks when cultured with DMSO. Compared with human hepatocytes, expression of P450s in HepaRG cells was in general lower with the exception for a considerably higher expression of CYP3A4 and CYP7A1. The expression of P450s generally decreased when DMSO was removed from the medium, whereas transporters and liver specific factors were unaffected. The relative mRNA content of drug metabolising P450s displayed the highest resemblance between human hepatocytes and differentiated HepaRG cells one day after removal of DMSO from the medium. The metabolism of midazolam, naloxone, and clozapine in HepaRG cells was similar to human hepatocytes, indicating the function of CYP3A4, CYP1A2, and UGT enzymes. However, the metabolism of 7-ethoxycoumarin and dextromethorphan was low, confirming low levels of CYP2E1 and CYP2D6 in HepaRG cells. The P450 probe substrates indicate a decrease in CYP1A2, CYP2B6, CYP2C9 and CYP3A4 activities in HepaRG cells one day after removal of DMSO from the medium. The activities were then relatively stable in DMSO free medium for up to 14 days. Based on the stable expression of liver specific functions over a long period in culture, the relative mRNA content of drug metabolising P450s and metabolic properties, HepaRG cells provide a valuable in vitro model for human drug metabolism studies.


Key words: CYP expression, cytochrome P450, drug clearance, hepatocytes, nuclear receptors, phase II drug metabolism, PXR





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.